GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes.
AIMS: A subset of patients who present as if they have Type 2 diabetes have positive pancreatic autoantibodies, and have been referred to as having latent autoimmune diabetes in adults (LADA). We assessed the prevalence and clinical characteristics of patients with glutamic acid decarboxylase antibo...
| Үндсэн зохиолчид: | , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
2006
|
| _version_ | 1826277906528075776 |
|---|---|
| author | Castleden, H Shields, B Bingley, P Williams, A Sampson, M Walker, M Gibson, J McCarthy, M Hitman, G Levy, J Hattersley, A Vaidya, B Pearson, E |
| author_facet | Castleden, H Shields, B Bingley, P Williams, A Sampson, M Walker, M Gibson, J McCarthy, M Hitman, G Levy, J Hattersley, A Vaidya, B Pearson, E |
| author_sort | Castleden, H |
| collection | OXFORD |
| description | AIMS: A subset of patients who present as if they have Type 2 diabetes have positive pancreatic autoantibodies, and have been referred to as having latent autoimmune diabetes in adults (LADA). We assessed the prevalence and clinical characteristics of patients with glutamic acid decarboxylase antibodies (GADA) in a cohort clinically selected for Type 2 diabetes and determined the presence of diabetes and GADA in their first-degree relatives. METHODS: GADA were measured in 2059 subjects, not known to be related, and clinically selected as having Type 2 diabetes for genetic studies. Clinical characteristics were compared in GADA positive and GADA negative subjects. Diabetes and GAD antibody status were compared in 208 first-degree relatives of GADA positive and GADA negative probands. RESULTS: Of the subjects, 136 (7%) were GADA positive. Compared with the GADA negative subjects, they were slimmer (P < 0.001), diagnosed at a younger age (P = 0.011) and progressed to insulin faster (P < 0.001). Thirty-three per cent of GADA positive subjects had a first-degree relative with diabetes compared with 42% of GADA negative subjects (P = 0.034). The overall prevalence of GADA was similar in the first-degree relatives of GADA positive and GADA negative probands (4 v 5%), and 19 of 22 (86%) diabetic relatives of GADA positive probands were GADA negative. CONCLUSION: Despite clinically selecting a Type 2 diabetes cohort, 7% were GADA positive with an altered phenotype. These GADA positive patients had a strong family history of non-autoimmune diabetes. This suggests that, in this subgroup of patients, autoimmune pancreatic beta-cell destruction occurs on a background of Type 2 diabetes genetic susceptibility. |
| first_indexed | 2024-03-06T23:35:57Z |
| format | Journal article |
| id | oxford-uuid:6da86db9-d4e8-4e84-9181-a3ec7c13b3cd |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:35:57Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:6da86db9-d4e8-4e84-9181-a3ec7c13b3cd2022-03-26T19:19:16ZGAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6da86db9-d4e8-4e84-9181-a3ec7c13b3cdEnglishSymplectic Elements at Oxford2006Castleden, HShields, BBingley, PWilliams, ASampson, MWalker, MGibson, JMcCarthy, MHitman, GLevy, JHattersley, AVaidya, BPearson, EAIMS: A subset of patients who present as if they have Type 2 diabetes have positive pancreatic autoantibodies, and have been referred to as having latent autoimmune diabetes in adults (LADA). We assessed the prevalence and clinical characteristics of patients with glutamic acid decarboxylase antibodies (GADA) in a cohort clinically selected for Type 2 diabetes and determined the presence of diabetes and GADA in their first-degree relatives. METHODS: GADA were measured in 2059 subjects, not known to be related, and clinically selected as having Type 2 diabetes for genetic studies. Clinical characteristics were compared in GADA positive and GADA negative subjects. Diabetes and GAD antibody status were compared in 208 first-degree relatives of GADA positive and GADA negative probands. RESULTS: Of the subjects, 136 (7%) were GADA positive. Compared with the GADA negative subjects, they were slimmer (P < 0.001), diagnosed at a younger age (P = 0.011) and progressed to insulin faster (P < 0.001). Thirty-three per cent of GADA positive subjects had a first-degree relative with diabetes compared with 42% of GADA negative subjects (P = 0.034). The overall prevalence of GADA was similar in the first-degree relatives of GADA positive and GADA negative probands (4 v 5%), and 19 of 22 (86%) diabetic relatives of GADA positive probands were GADA negative. CONCLUSION: Despite clinically selecting a Type 2 diabetes cohort, 7% were GADA positive with an altered phenotype. These GADA positive patients had a strong family history of non-autoimmune diabetes. This suggests that, in this subgroup of patients, autoimmune pancreatic beta-cell destruction occurs on a background of Type 2 diabetes genetic susceptibility. |
| spellingShingle | Castleden, H Shields, B Bingley, P Williams, A Sampson, M Walker, M Gibson, J McCarthy, M Hitman, G Levy, J Hattersley, A Vaidya, B Pearson, E GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. |
| title | GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. |
| title_full | GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. |
| title_fullStr | GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. |
| title_full_unstemmed | GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. |
| title_short | GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. |
| title_sort | gad antibodies in probands and their relatives in a cohort clinically selected for type 2 diabetes |
| work_keys_str_mv | AT castledenh gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT shieldsb gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT bingleyp gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT williamsa gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT sampsonm gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT walkerm gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT gibsonj gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT mccarthym gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT hitmang gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT levyj gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT hattersleya gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT vaidyab gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes AT pearsone gadantibodiesinprobandsandtheirrelativesinacohortclinicallyselectedfortype2diabetes |